⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication.
"My dose hasn't been increased — should I ask my doctor?" and "I increased my dose and feel terrible — is this normal?" are among the most common questions in Indian GLP-1 communities. Dose titration — the process of gradually increasing your GLP-1 medication to the target therapeutic dose — is one of the most important and most misunderstood aspects of GLP-1 therapy.
Get it right and you maximise benefits while minimising side effects. Rush it and you face weeks of severe nausea and vomiting. Delay it unnecessarily and you leave significant benefits on the table.
This guide covers the complete titration schedules for every major GLP-1 medication available in India, how to know when you are ready to increase, and the critical mistakes to avoid.
GLP-1 medications work by activating receptors in the brain's appetite control centre, slowing stomach emptying, and stimulating insulin release. At the target therapeutic dose, these effects are powerful. But at the target dose from day one, nausea, vomiting, and diarrhoea would be so severe that most people would stop the medication immediately.
Titration is the solution: starting at a low dose allows your gut and brain to gradually adapt. Over weeks to months, the body adjusts, side effects diminish, and the dose is incrementally raised toward the full therapeutic level.
Key principle: Titration is not optional. Patients who skip titration and jump straight to high doses have dramatically higher discontinuation rates due to intolerance.
Both are once-weekly subcutaneous injections.
Ozempic — Standard diabetes titration:
| Phase | Dose | Duration |
|---|---|---|
| Starting | 0.25 mg once weekly | 4 weeks |
| Step 2 | 0.5 mg once weekly | 4 weeks minimum |
| Maintenance | 1.0 mg once weekly | Ongoing (some stay at 0.5 mg if goals are met) |
Many Indian endocrinologists keep diabetes patients at 0.5 mg if HbA1c goals are met, to minimise side effects and cost. There is no obligation to reach 1 mg if you are already at target.
Wegovy — Weight management full titration to 2.4 mg:
| Phase | Dose | Duration |
|---|---|---|
| Starting | 0.25 mg once weekly | 4 weeks |
| Step 2 | 0.5 mg once weekly | 4 weeks |
| Step 3 | 1.0 mg once weekly | 4 weeks |
| Step 4 | 1.7 mg once weekly | 4 weeks |
| Maintenance | 2.4 mg once weekly | Ongoing |
Total titration period: approximately 17–20 weeks (4–5 months). This schedule is designed to be followed as written. Compressing it causes a sharp increase in GI side effects.
Liraglutide is a once-daily injection. Victoza is available in India; Saxenda availability varies by city.
Victoza — Diabetes titration:
| Phase | Dose | Duration |
|---|---|---|
| Starting | 0.6 mg once daily | 1 week |
| Step 2 | 1.2 mg once daily | 1 week (many stay here) |
| Maintenance | 1.8 mg once daily | Ongoing if tolerated |
Saxenda — Weight management titration:
| Phase | Dose | Duration |
|---|---|---|
| Week 1 | 0.6 mg once daily | 7 days |
| Week 2 | 1.2 mg once daily | 7 days |
| Week 3 | 1.8 mg once daily | 7 days |
| Week 4 | 2.4 mg once daily | 7 days |
| Week 5+ | 3.0 mg once daily | Maintenance |
Total titration for Saxenda is only 5 weeks — faster than semaglutide, but with proportionally more week-to-week side effect fluctuation due to daily dosing.
Tirzepatide (Mounjaro) is a dual GLP-1 and GIP receptor agonist, injected once weekly. Available in India as of 2024.
| Phase | Dose | Duration |
|---|---|---|
| Starting | 2.5 mg once weekly | 4 weeks |
| Step 2 | 5 mg once weekly | 4 weeks |
| Step 3 | 7.5 mg once weekly | 4 weeks |
| Step 4 | 10 mg once weekly | 4 weeks |
| Step 5 | 12.5 mg once weekly | 4 weeks |
| Maintenance | 15 mg once weekly | Ongoing |
Total titration: approximately 5–6 months. Tirzepatide generally causes somewhat more GI side effects at higher doses than semaglutide alone — do not rush this schedule.
Note: Not everyone needs to reach 15 mg. Many patients achieve their goals at 5 mg or 10 mg with fewer side effects.
Consider increasing to the next dose step when all of the following are true:
Delay the dose increase if:
The manufacturer's schedules represent the minimum time per dose step. There is no upper limit. If you experience significant nausea at a dose step, staying at that dose for 6, 8, or even 12 weeks before advancing is perfectly safe.
Many Indian endocrinologists now routinely prescribe 6–8 weeks per dose step for patients who experience moderate nausea. Slower titration means:
A common scenario in Indian clinics: patients are kept at 0.5 mg semaglutide for 3 months because side effects are manageable and blood sugar goals are already met. Advancing to 1 mg is not necessary for these patients.
Patients sometimes need to stop GLP-1 entirely — before major surgery (typically 2 weeks in advance), during hospitalisation, or during severe illness. When restarting after a break of more than 2 weeks, you must restart from the lowest starting dose and titrate up again, even if you were previously on the highest dose.
Never resume at the high dose after a holiday. Resuming at 1 mg semaglutide or 3 mg liraglutide after a 3-week pause will cause severe GI side effects, as your body has lost its adaptation to the higher dose.
| Mistake | Correct Approach |
|---|---|
| Increasing dose because weight loss has slowed | Plateau is not always a sign to increase dose — evaluate diet and activity first |
| Skipping injections to manage nausea | Stay at current dose longer; never skip — discuss with doctor |
| Restarting at the last dose after a gap | Always restart from the starting dose |
| Changing dose without telling your doctor | All changes should involve your prescriber |
| Staying at the starting dose indefinitely | 0.25 mg semaglutide has minimal therapeutic effect — titration is necessary |
| Comparing titration pace with someone online | Individual tolerance varies; your pace should match your response, not others' |
A common trigger for wanting to increase dose quickly is the dreaded "weight loss plateau" — the body's natural adaptation to the lower energy intake. Before attributing a plateau to insufficient dose, evaluate whether:
Only if these factors are addressed and weight loss still does not resume over 8–12 weeks should dose increase be discussed with your doctor as one option.
Seek medical advice promptly if:
Q: I have been at 0.25 mg semaglutide for 3 months and my doctor hasn't increased it. Is this normal? 0.25 mg is the initiating dose only — it has minimal therapeutic effect on blood sugar or weight. If your doctor is intentionally keeping you here due to ongoing severe side effects, that is a valid medical decision. If it appears to have been overlooked, raise it at your next appointment.
Q: Nausea came back badly after my dose increase. Is this normal? Yes. Each dose step can cause a brief recurrence of nausea as the body adapts to the higher level. This typically improves within 1–2 weeks. If it is severe and persistent beyond 2–3 weeks, consult your doctor about whether to stay at the current dose longer.
Q: Can I stay at a lower dose permanently if it is working? Absolutely. If your blood sugar or weight goals are being met at a lower dose with good tolerability, there is no obligation to escalate further. The maximum doses in the titration schedules are upper limits, not requirements.
Q: I am on Ozempic 1 mg but my friend is on Wegovy 2.4 mg — are they the same medication? Yes — both contain semaglutide, but Ozempic is approved in India for Type 2 diabetes (maximum 1 mg) while Wegovy is approved for chronic weight management (titrates to 2.4 mg). The therapeutic goal, dosing schedules, and pen presentations differ.
Consult your healthcare provider before starting any medication or making any changes to your GLP-1 dosing schedule. Never adjust your dose without your doctor's guidance.
